文献速递头颈部肿瘤放疗

头颈部副神经节瘤的立体定向放疗:治疗反应需要等待多久

Stereotactic radiotherapy for head and neck paragangliomas: How long should we wait for treatment response?
PubMed 文献 · Radiother Oncol · 2024-03-16

63例头颈部副神经节瘤患者接受根治性立体定向放疗并回顾性分析,共照射68个病灶。中位随访40个月,总体肿瘤体积缩小率为62%,达到肿瘤体积缩小的中位时间为9个月,42%的病例在12个月及以上才出现肿瘤体积缩小。局部控制率为100%,未观察到≥3级急性和晚期毒性。

要点

  • 总体肿瘤体积缩小率为62%,达到肿瘤体积缩小的中位时间为9个月。
  • 42%的病例肿瘤体积缩小发生在12个月及以上,中位随访40个月。
  • 局部控制率为100%,未观察到≥3级急性和晚期毒性。

核心结论

  • 立体定向放疗对头颈部副神经节瘤的局部控制率极佳,但治疗反应可能需要时间,相当比例患者的肿瘤体积缩小可持续至治疗第一年之后。

研究设计与样本

  • 回顾性评估63例接受根治性立体定向放疗的头颈部副神经节瘤病例,共照射68个病灶,使用SPSS v23.0进行统计分析。

主要发现

  • 68个病灶中颈静脉鼓室球瘤最常见,占44%。
  • 中位肿瘤直径3 cm(范围1-7.6 cm),中位肿瘤体积15.4 cm3(范围1-185 cm3)。
  • 中位剂量25 Gy(范围12-37.5 Gy),分5次(范围1-5次)。
  • 中位随访40个月(范围3-184个月),总体肿瘤体积缩小率为62%。
  • 达到肿瘤体积缩小的中位时间为9个月(范围3-36个月),42%的病例在12个月及以上出现肿瘤体积缩小。

关键数值与推荐

  • 放疗后中位4.6个月(范围3-11个月)评估时,26例(41%)出现肿瘤体积缩小。
  • 随访期间另有13例出现肿瘤体积缩小,总体肿瘤体积缩小率为62%。
  • 未接受过手术的患者肿瘤体积缩小率更高(p = 0.03),随访时间更长的患者肿瘤体积缩小率更高(p = 0.04)。
  • 肿瘤体积缩小的可能性随立体定向放疗剂量增加呈升高趋势(p = 0.06)。
  • 总体局部控制率为100%,未观察到≥3级急性和晚期毒性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Stereotactic radiotherapy (SRT) is an effective treatment for head & neck (H&N) paragangliomas. Nevertheless, the timeline for achieving a tumor-volume-reduction (TVR) remains unclear. MATERIALS AND METHODS: Sixty-three cases with H&N paragangliomas received definitive SRT and were evaluated retrospectively. Statistical Package for the Social Sciences (SPSS) v23.0 (IBM, Armonk, NY, USA) was used for statistics. RESULTS: Sixty-eight lesions were irradiated, with glomus jugulotympanicum being the most common location (44 %). Median tumor diameter and volume were 3 cm (range, 1-7.6 cm) and 15.4 cm3 (range,1-185 cm3), respectively. Median dose was 25 Gy (range, 12-37.5 Gy) in 5 fractions (range, 1-5 fractions). Median follow-up was 40 months (range, 3-184 months). Treatment response, evaluated at a median 4.6 months post-SRT (range: 3-11 months), revealed TVR in 26 cases (41 %). During follow-up, 13 additional cases showed TVR, resulting in an overall TVR rate of 62 %. The median duration for attaining TVR was 9 months (range, 3-36 months) after SRT, and TVR occurred ≥ 12 months in 42 % of cases. Patients without prior surgery (p = 0.03) and with a longer follow-up (p = 0.04) demonstrated a higher rate of TVR. The likelihood of TVR tends to increase as the SRT dose increases (p = 0.06). Overall local control (LC) rate was 100 %. No ≥ grade 3 acute or late toxicities were observed. CONCLUSION: While SRT demonstrates an excellent LC rate for H&N paragangliomas, it's important to note that the response to treatment may require time. TVR may last beyond the initial year of treatment in a substantial proportion of patients.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Yazici G, Kahvecioglu A, Yuce Sari S, et al. Stereotactic radiotherapy for head and neck paragangliomas: How long should we wait for treatment response? Radiother Oncol. 2024. PMID: 38499272. doi:10.1016/j.radonc.2024.110232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。